Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure

Gynecologic Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles